dnajb1-prkaca peptide vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 29, 2020 (NCT04248569)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04248569 | Phase 1 | Feb 29, 2020 | Bristol-Myers Squibb, Fibrolamellar Cancer Foundation, Johns Hopkins University, National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2020 |
| Fibrolamellar Cancer Foundation | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1